# Renal denervation system

Technology · id `cardio:renal-denervation-system` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Renal denervation catheter; Ablation catheter, renal denervation

Browse, organ or system: Blood vessels; Kidneys  
Browse, condition area: High blood pressure  

## In plain language

A renal denervation system is the equipment used for renal denervation: an ablation catheter for the renal arteries and the console that powers it. FDA files these catheters under one product code, QYI, in class 3, and defines them as for denervating the renal nerves to lower blood pressure. Two systems received US premarket approval in November 2023: an ultrasound system (P220023, approved 7 November 2023) and a radiofrequency system (P220026, approved 17 November 2023). Their original approval orders, the only ones read (later supplements were not), state the same indication: to reduce blood pressure as an adjunctive treatment in people with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. This page records no study of benefit or harm.

## Technical summary

FDA product code QYI (Ablation Catheter, Renal Denervation), class 3, is an exact match; the openFDA record gives no regulation number. Approval facts are read from the original orders only: P220023 (Paradise Ultrasound Renal Denervation System; Recor Medical, Inc.; APPR 2023-11-07) and P220026 (Symplicity Spyral Multi-Electrode Renal Denervation Catheter with the Symplicity G3 RF Generator; Medtronic, Inc.; APPR 2023-11-17). Later supplements were not read. No MeSH descriptor was found. The procedure has its own page.

## Claims, with the population each applies to

## Context: Renal denervation ablation catheters as classified by the US FDA under product code QYI

Recipient: No clinical recipient; Population: Not applicable: the classification record describes a device type, not a patient group.; Care setting: Not stated in the classification record; Geography: United States (FDA device classification record); Life stage: Not applicable; Follow-up: Not applicable (regulatory classification)

### The openFDA device classification for product code QYI names the device type ablation catheter, renal denervation, in class 3, and defines it as for denervating the renal nerves to lower blood pressure.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: No clinical recipient; Population: Not applicable: the classification record describes a device type, not a patient group.; Care setting: Not stated in the classification record; Geography: United States (FDA device classification record); Life stage: Not applicable; Follow-up: Not applicable (regulatory classification)
- Limitations: A regulatory classification, not a finding about benefit or safety. The record gives no regulation number and no device description beyond its one-line definition. openFDA says its data are unvalidated and not to be relied on for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA device classification, product code QYI (Ablation Catheter, Renal Denervation) (Regulator, edition The openFDA device classification record returned on 2026-11-18 for product code QYI, from a dataset last updated 2026-11-09.) <https://api.fda.gov/device/classification.json?search=product_code:QYI>
     Locator: results\[0\].product\_code. Retrieved 2026-11-18T17:25:56Z. Source state: Current. Version fingerprint: dba9f4a3a4384c8b3d22e8d08150d06b13ae155ef7ca922d31c65d63bd945f85.
     How it applies: Quoted at this locator.
  2. Supports: openFDA device classification, product code QYI (Ablation Catheter, Renal Denervation) (Regulator, edition The openFDA device classification record returned on 2026-11-18 for product code QYI, from a dataset last updated 2026-11-09.) <https://api.fda.gov/device/classification.json?search=product_code:QYI>
     Locator: results\[0\].device\_name. Retrieved 2026-11-18T17:25:56Z. Source state: Current. Version fingerprint: dba9f4a3a4384c8b3d22e8d08150d06b13ae155ef7ca922d31c65d63bd945f85.
     How it applies: Quoted at this locator.
  3. Supports: openFDA device classification, product code QYI (Ablation Catheter, Renal Denervation) (Regulator, edition The openFDA device classification record returned on 2026-11-18 for product code QYI, from a dataset last updated 2026-11-09.) <https://api.fda.gov/device/classification.json?search=product_code:QYI>
     Locator: results\[0\].device\_class. Retrieved 2026-11-18T17:25:56Z. Source state: Current. Version fingerprint: dba9f4a3a4384c8b3d22e8d08150d06b13ae155ef7ca922d31c65d63bd945f85.
     How it applies: Quoted at this locator.
  4. Supports: openFDA device classification, product code QYI (Ablation Catheter, Renal Denervation) (Regulator, edition The openFDA device classification record returned on 2026-11-18 for product code QYI, from a dataset last updated 2026-11-09.) <https://api.fda.gov/device/classification.json?search=product_code:QYI>
     Locator: results\[0\].definition. Retrieved 2026-11-18T17:25:56Z. Source state: Current. Version fingerprint: dba9f4a3a4384c8b3d22e8d08150d06b13ae155ef7ca922d31c65d63bd945f85.
     How it applies: Quoted at this locator.

## Context: Patients with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure, as the US approval orders of two renal denervation systems state

Recipient: Recipient not specified; Population: Patients with hypertension whose blood pressure is not adequately controlled by lifestyle modifications and antihypertensive medications, as the two approval orders word it. The statements read give no age group.; Care setting: Renal denervation system used as an adjunctive treatment (the orders' words); Geography: United States (FDA premarket approval records); Life stage: Not stated in the statements read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory statements)

### Two premarket approvals under product code QYI state an indication for renal denervation systems. The openFDA record of P220023 (Recor Medical, Inc., decision APPR, 7 November 2023) says the Paradise Ultrasound Renal Denervation System is indicated to reduce blood pressure as an adjunctive treatment in hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. The openFDA record of P220026 (Medtronic, Inc., decision APPR, 17 November 2023) says the Symplicity Spyral Multi-Electrode Renal Denervation Catheter and the Symplicity G3 RF Generator are indicated to reduce blood pressure as an adjunctive treatment in patients with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients with hypertension whose blood pressure is not adequately controlled by lifestyle modifications and antihypertensive medications, as the two approval orders word it. The statements read give no age group.; Care setting: Renal denervation system used as an adjunctive treatment (the orders' words); Geography: United States (FDA premarket approval records); Life stage: Not stated in the statements read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory statements)
- Limitations: This claim covers the two original approval orders only. Each approval has later supplements in openFDA; they were not read and may change the wording, the devices or the conditions of use. An FDA approval is a decision about a device, not a finding about how well it works. The orders do not use the term resistant hypertension. openFDA says its data are unvalidated and not to be relied on for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: FDA premarket approval P220023: Paradise Ultrasound Renal Denervation System (openFDA record of the original approval) (Regulator, edition The openFDA PMA record of the original approval of P220023 (decision date 2023-11-07), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220023 in openFDA were not read.) <https://api.fda.gov/device/pma.json?search=pma_number:P220023>
     Locator: results\[0\].pma\_number. Retrieved 2026-11-18T17:25:58Z. Source state: Current. Version fingerprint: 5fd9d7c59de3fbc4aac32d2f8983ebb03a6e72cdd1e6192b1926f23ac4ceb913.
     How it applies: Quoted at this locator.
  2. Supports: FDA premarket approval P220023: Paradise Ultrasound Renal Denervation System (openFDA record of the original approval) (Regulator, edition The openFDA PMA record of the original approval of P220023 (decision date 2023-11-07), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220023 in openFDA were not read.) <https://api.fda.gov/device/pma.json?search=pma_number:P220023>
     Locator: results\[0\].applicant. Retrieved 2026-11-18T17:25:58Z. Source state: Current. Version fingerprint: 5fd9d7c59de3fbc4aac32d2f8983ebb03a6e72cdd1e6192b1926f23ac4ceb913.
     How it applies: Quoted at this locator.
  3. Supports: FDA premarket approval P220023: Paradise Ultrasound Renal Denervation System (openFDA record of the original approval) (Regulator, edition The openFDA PMA record of the original approval of P220023 (decision date 2023-11-07), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220023 in openFDA were not read.) <https://api.fda.gov/device/pma.json?search=pma_number:P220023>
     Locator: results\[0\].decision\_date. Retrieved 2026-11-18T17:25:58Z. Source state: Current. Version fingerprint: 5fd9d7c59de3fbc4aac32d2f8983ebb03a6e72cdd1e6192b1926f23ac4ceb913.
     How it applies: Quoted at this locator.
  4. Supports: FDA premarket approval P220023: Paradise Ultrasound Renal Denervation System (openFDA record of the original approval) (Regulator, edition The openFDA PMA record of the original approval of P220023 (decision date 2023-11-07), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220023 in openFDA were not read.) <https://api.fda.gov/device/pma.json?search=pma_number:P220023>
     Locator: results\[0\].decision\_code. Retrieved 2026-11-18T17:25:58Z. Source state: Current. Version fingerprint: 5fd9d7c59de3fbc4aac32d2f8983ebb03a6e72cdd1e6192b1926f23ac4ceb913.
     How it applies: Quoted at this locator.
  5. Supports: FDA premarket approval P220023: Paradise Ultrasound Renal Denervation System (openFDA record of the original approval) (Regulator, edition The openFDA PMA record of the original approval of P220023 (decision date 2023-11-07), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220023 in openFDA were not read.) <https://api.fda.gov/device/pma.json?search=pma_number:P220023>
     Locator: results\[0\].product\_code. Retrieved 2026-11-18T17:25:58Z. Source state: Current. Version fingerprint: 5fd9d7c59de3fbc4aac32d2f8983ebb03a6e72cdd1e6192b1926f23ac4ceb913.
     How it applies: Quoted at this locator.
  6. Supports: FDA premarket approval P220023: Paradise Ultrasound Renal Denervation System (openFDA record of the original approval) (Regulator, edition The openFDA PMA record of the original approval of P220023 (decision date 2023-11-07), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220023 in openFDA were not read.) <https://api.fda.gov/device/pma.json?search=pma_number:P220023>
     Locator: results\[0\].ao\_statement, fragment 1 of 2. Retrieved 2026-11-18T17:25:58Z. Source state: Current. Version fingerprint: 5fd9d7c59de3fbc4aac32d2f8983ebb03a6e72cdd1e6192b1926f23ac4ceb913.
     How it applies: Quoted at this locator.
  7. Supports: FDA premarket approval P220023: Paradise Ultrasound Renal Denervation System (openFDA record of the original approval) (Regulator, edition The openFDA PMA record of the original approval of P220023 (decision date 2023-11-07), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220023 in openFDA were not read.) <https://api.fda.gov/device/pma.json?search=pma_number:P220023>
     Locator: results\[0\].ao\_statement, fragment 2 of 2. Retrieved 2026-11-18T17:25:58Z. Source state: Current. Version fingerprint: 5fd9d7c59de3fbc4aac32d2f8983ebb03a6e72cdd1e6192b1926f23ac4ceb913.
     How it applies: Quoted at this locator.
  8. Supports: FDA premarket approval P220026: Symplicity Spyral Renal Denervation System (openFDA record of the original approval) (Regulator, edition The openFDA PMA record of the original approval of P220026 (decision date 2023-11-17), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220026 in openFDA were not read. The record's trade name field holds a stray control character, so no quote is taken from it.) <https://api.fda.gov/device/pma.json?search=pma_number:P220026>
     Locator: results\[0\].pma\_number. Retrieved 2026-11-18T17:25:59Z. Source state: Current. Version fingerprint: d824b3e99fa085f7f599e8a5f9ab199b7fbe589e947c9eeea89082709f3a2629.
     How it applies: Quoted at this locator.
  9. Supports: FDA premarket approval P220026: Symplicity Spyral Renal Denervation System (openFDA record of the original approval) (Regulator, edition The openFDA PMA record of the original approval of P220026 (decision date 2023-11-17), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220026 in openFDA were not read. The record's trade name field holds a stray control character, so no quote is taken from it.) <https://api.fda.gov/device/pma.json?search=pma_number:P220026>
     Locator: results\[0\].applicant. Retrieved 2026-11-18T17:25:59Z. Source state: Current. Version fingerprint: d824b3e99fa085f7f599e8a5f9ab199b7fbe589e947c9eeea89082709f3a2629.
     How it applies: Quoted at this locator.
  10. Supports: FDA premarket approval P220026: Symplicity Spyral Renal Denervation System (openFDA record of the original approval) (Regulator, edition The openFDA PMA record of the original approval of P220026 (decision date 2023-11-17), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220026 in openFDA were not read. The record's trade name field holds a stray control character, so no quote is taken from it.) <https://api.fda.gov/device/pma.json?search=pma_number:P220026>
     Locator: results\[0\].decision\_date. Retrieved 2026-11-18T17:25:59Z. Source state: Current. Version fingerprint: d824b3e99fa085f7f599e8a5f9ab199b7fbe589e947c9eeea89082709f3a2629.
     How it applies: Quoted at this locator.
  11. Supports: FDA premarket approval P220026: Symplicity Spyral Renal Denervation System (openFDA record of the original approval) (Regulator, edition The openFDA PMA record of the original approval of P220026 (decision date 2023-11-17), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220026 in openFDA were not read. The record's trade name field holds a stray control character, so no quote is taken from it.) <https://api.fda.gov/device/pma.json?search=pma_number:P220026>
     Locator: results\[0\].decision\_code. Retrieved 2026-11-18T17:25:59Z. Source state: Current. Version fingerprint: d824b3e99fa085f7f599e8a5f9ab199b7fbe589e947c9eeea89082709f3a2629.
     How it applies: Quoted at this locator.
  12. Supports: FDA premarket approval P220026: Symplicity Spyral Renal Denervation System (openFDA record of the original approval) (Regulator, edition The openFDA PMA record of the original approval of P220026 (decision date 2023-11-17), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220026 in openFDA were not read. The record's trade name field holds a stray control character, so no quote is taken from it.) <https://api.fda.gov/device/pma.json?search=pma_number:P220026>
     Locator: results\[0\].product\_code. Retrieved 2026-11-18T17:25:59Z. Source state: Current. Version fingerprint: d824b3e99fa085f7f599e8a5f9ab199b7fbe589e947c9eeea89082709f3a2629.
     How it applies: Quoted at this locator.
  13. Supports: FDA premarket approval P220026: Symplicity Spyral Renal Denervation System (openFDA record of the original approval) (Regulator, edition The openFDA PMA record of the original approval of P220026 (decision date 2023-11-17), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220026 in openFDA were not read. The record's trade name field holds a stray control character, so no quote is taken from it.) <https://api.fda.gov/device/pma.json?search=pma_number:P220026>
     Locator: results\[0\].ao\_statement, fragment 1 of 2. Retrieved 2026-11-18T17:25:59Z. Source state: Current. Version fingerprint: d824b3e99fa085f7f599e8a5f9ab199b7fbe589e947c9eeea89082709f3a2629.
     How it applies: Quoted at this locator.
  14. Supports: FDA premarket approval P220026: Symplicity Spyral Renal Denervation System (openFDA record of the original approval) (Regulator, edition The openFDA PMA record of the original approval of P220026 (decision date 2023-11-17), the earliest by decision date, returned on 2026-11-18, dataset last updated 2026-11-09. The later supplements of P220026 in openFDA were not read. The record's trade name field holds a stray control character, so no quote is taken from it.) <https://api.fda.gov/device/pma.json?search=pma_number:P220026>
     Locator: results\[0\].ao\_statement, fragment 2 of 2. Retrieved 2026-11-18T17:25:59Z. Source state: Current. Version fingerprint: d824b3e99fa085f7f599e8a5f9ab199b7fbe589e947c9eeea89082709f3a2629.
     How it applies: Quoted at this locator.

## Connected pages

- US approval orders state an indication in hypertension that is not adequately controlled by lifestyle modifications and medications: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-renal-denervation-pma-indications` and its context]
- Filed under this front: Devices and monitoring (`cardio:front-devices-and-monitoring`)
- Used by: Renal denervation (`cardio:renal-denervation`)

## Provenance

Content hash: 85744aaf1fd3fc494ec00b5215c40d347a0852ba1777f139857afd2d1b2681a3
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
